 Zacks Investment Research upgraded shares of Millendo Therapeutics NASDAQ:MLND from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Research currently has 1.75 target price on the stock. According to Zacks, Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan ... 